We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

45 hedge funds and large institutions have $3.53M invested in Protalix BioTherapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 20 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more call options, than puts

Call options by funds: $62K | Put options by funds: $37K

3.02% less ownership

Funds ownership: 7.69% → 4.67% (-3%)

32% less funds holding

Funds holding: 66 → 45 (-21)

47% less capital invested

Capital invested by funds: $6.6M → $3.53M (-$3.07M)

75% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 20

78% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 27

Holders
45
Holders Change
-21
Holders Change %
-31.82%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
20
Closed
27
Calls
$62K
Puts
$37K
Net Calls
+$25K
Net Calls Change
-$95K

Top Buyers

Rank Fund Capital Flow
1
SWP
Stratos Wealth Partners
Ohio
+$284K
2
Renaissance Technologies
Renaissance Technologies
New York
+$159K
3
Citadel Advisors
Citadel Advisors
Florida
+$77K
4
VF
Virtu Financial
New York
+$45.6K
5
SA
Sanctuary Advisors
Indiana
+$39K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$460K
2
Goldman Sachs
Goldman Sachs
New York
-$433K
3
Northern Trust
Northern Trust
Illinois
-$390K
4
Jane Street
Jane Street
New York
-$257K
5
YIH
Y-Intercept (HK)
Hong Kong
-$185K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
26
Aptus Capital Advisors
Alabama
$22.8K +$1.49K +1,412 +7%
KAS
27
Kestra Advisory Services
Texas
$16.3K – – –
Lido Advisors
28
Lido Advisors
California
$15.9K – – –
FI
29
Finivi Inc
Massachusetts
$14.8K – – –
AS
30
Altshuler Shaham
Israel
$12.4K – – –
PD
31
Point72 (DIFC)
United Arab Emirates
$11.8K +$12.2K +11,600 New
CFM
32
Catalyst Funds Management
Australia
$10.4K – – –
HIM
33
Harbour Investment Management
Washington
$10.3K – – –
TWC
34
TD Waterhouse Canada
Ontario, Canada
$6.24K – – –
National Bank of Canada
35
National Bank of Canada
Quebec, Canada
$6.12K -$105 -100 -2%
TRCT
36
Tower Research Capital (TRC)
New York
$5.16K -$13.5K -12,824 -72%
Simplex Trading
37
Simplex Trading
Illinois
$3K +$3.52K +3,347 +4,996%
TC
38
Truvestments Capital
Florida
$2.51K +$2.58K +2,458 New
JP Morgan Chase
39
JP Morgan Chase
New York
$1.63K – – –
AWM
40
Activest Wealth Management
Florida
$306 – – –
UBS Group
41
UBS Group
Switzerland
$298 -$16 -15 -5%
FDCDDQ
42
Federation des caisses Desjardins du Quebec
Quebec, Canada
$255 – – –
YDMI
43
Y.D. More Investments
Israel
$224 – – –
Osaic Holdings
44
Osaic Holdings
Arizona
$204 -$1.47K -1,400 -88%
AAP
45
Arax Advisory Partners
Colorado
$40 – – –
YIH
46
Y-Intercept (HK)
Hong Kong
– -$185K -158,259 Closed
CC
47
Centiva Capital
New York
– -$152K -130,332 Closed
HF
48
HRT Financial
New York
– -$93K -80,224 Closed
PP
49
Paloma Partners
Connecticut
– -$92.9K -79,442 Closed
GSC
50
Ground Swell Capital
South Carolina
– -$72.8K -62,234 Closed
1
2
3

PLX Hedge Fund Activity: Q3 2024 in Review

45 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2024, worth a combined $3.53M — down 47% from $6.6M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of PLX and 6 opened new positions — a net loss of 21 holders — while 20 trimmed existing stakes and 5 added.

The largest buyer was Stratos Wealth Partners, opening a new position worth an estimated $284K. The largest seller was Millennium Management, cutting an estimated $460K.

  • 45 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2024, down from 66 in Q2 2024.
  • Funds reported $3.53M of Protalix BioTherapeutics stock for Q3 2024, down 47% quarter-over-quarter.
  • 6 funds opened new Protalix BioTherapeutics positions in Q3 2024 and 27 closed out, a net change of -21 holders.
  • The largest Protalix BioTherapeutics buyer in Q3 2024 was Stratos Wealth Partners, an estimated $284K added.
  • The largest Protalix BioTherapeutics seller in Q3 2024 was Millennium Management, an estimated $460K sold.

Based on aggregated 13F filings for Q3 2024.